Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation

NCT01615757 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Ara-c
DRUG: Ara-c

Sponsor

All India Institute of Medical Sciences